Evidence map›Paper›PMID 32333508›Full record

ArticleChemMedChem2020

Biological Characterization, Mechanistic Investigation and Structure-Activity Relationships of Chemically Stable TLR2 Antagonists.

Marcel Bermudez, Maria Grabowski, Manuela S Murgueitio, Markus Tiemann, Péter Varga, Thomas Rudolf, Gerhard Wolber, Günther Weindl, Jörg Rademann

Open access · hybridAbstract read
In one paragraph

Article in ChemMedChem, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Recognition of Mycobacterium tuberculosis by macrophage Toll-like receptor and its role in autophagy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Review
  2. Review
  3. Review
  4. Article
  5. Frontiers in immunology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Marcel BermudezInstitute of Pharmacy (Pharmaceutical and Medicinal Chemistry), Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195, Berlin, Germany.ORCID 0000-0002-7421-3282
Maria GrabowskiInstitute of Pharmacy (Pharmacology and Toxicology), Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195, Berlin, Germany.
Manuela S MurgueitioInstitute of Pharmacy (Pharmaceutical and Medicinal Chemistry), Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195, Berlin, Germany.
Markus TiemannInstitute of Pharmacy (Pharmaceutical and Medicinal Chemistry), Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195, Berlin, Germany.
Péter VargaInstitute of Pharmacy (Pharmaceutical and Medicinal Chemistry), Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195, Berlin, Germany.
Thomas RudolfInstitute of Pharmacy (Pharmaceutical and Medicinal Chemistry), Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195, Berlin, Germany.
Gerhard WolberInstitute of Pharmacy (Pharmaceutical and Medicinal Chemistry), Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195, Berlin, Germany.ORCID 0000-0002-5344-0048
Günther WeindlInstitute of Pharmacy (Pharmacology and Toxicology), Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195, Berlin, Germany.ORCID 0000-0002-4493-7597
Jörg RademannInstitute of Pharmacy (Pharmaceutical and Medicinal Chemistry), Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195, Berlin, Germany.ORCID 0000-0001-6678-3165
Freie Universität Berlin · DEUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toll-like receptors (TLRs) build the first barrier in the innate immune response and therefore represent promising targets for the modulation of inflammatory processes. Recently, the pyrogallol-containing TLR2 antagonists CU-CPT22 and MMG-11 were reported; however, their 1,2,3-triphenol motif renders them highly susceptible to oxidation and excludes them from use in extended experiments under aerobic conditions. Therefore, we have developed a set of novel TLR2 antagonists (1-9) based on the systematic variation of substructures, linker elements, and the hydrogen-bonding pattern of the pyrogallol precursors by using chemically robust building blocks. The novel series of chemically stable and synthetically accessible TLR2 antagonists (1-9) was pharmacologically characterized, and the potential binding modes of the active compounds were evaluated structurally. Our results provide new insights into structure-activity relationships and allow rationalization of structural binding characteristics. Moreover, they support the hypothesis that this class of TLR ligands bind solely to TLR2 and do not directly interact with TLR1 or TLR6 of the functional heterodimer. The most active compound from this series (6), is chemically stable, nontoxic, TLR2-selective, and shows a similar activity with regard to the pyrogallol starting points, thus indicating the variability of the hydrogen bonding pattern.

Indexed as

Cells, CulturedDose-Response Relationship, DrugHEK293 CellsHumansLigandsMolecular StructurePyrogallolStructure-Activity RelationshipToll-Like Receptor 2LigandsPyrogallolTLR2 protein, humanToll-Like Receptor 2chemical synthesisinflammationmolecular modelingstructure-based designTLR selectivityToll-like receptors

Identifiers

PMID32333508
PMCPMC7496872
OpenAlexW3018293100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.